Veklury
Remdesivir + Corticosteroids Boost Survival in COVID-19 Patients With COPD
Early initiation of remdesivir (Veklury, Gilead Sciences) and corticosteroids in patients with COPD and COVID-19 ...
AUGUST 8, 2025
Veklury Appears to Reduce Risk for Long COVID
Remdesivir appears to reduce the risk for certain long COVID-19 symptoms in people who were hospitalized for ...
MARCH 7, 2024
Veklury Reduces Mortality in Immunocompromised People With COVID-19
Veklury can have significant benefits for immunocompromised people with COVID-19, reducing mortality by 30%.
MARCH 1, 2024
FDA Expands Indication for Veklury to Treat COVID-19 Patients With Renal Impairment
With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across ...
JULY 14, 2023
Optimizing Remdesivir Use
Henry Ford Health partnered with Premier Inc to standardize the use of remdesivir based on the evidence. The new ...
JUNE 17, 2022
FDA Approves Veklury, First COVID-19 Treatment for Young Children
The FDA expanded the approval of the COVID-19 drug remdesivir (Veklury, Gilead) to include pediatric patients 28 ...
APRIL 26, 2022
Remdesivir Resistance Found in Immunocompromised Patient
Yale researchers said the discovery raised concerns about the emergence of drug resistance in COVID-19 patients, ...
MARCH 24, 2022
FDA Expands Use of Veklury for Mild to Moderate COVID-19
Previously limited to hospitalized patients, The FDA expands use of remdesivir to the outpatient setting.
JANUARY 24, 2022